Partner Content: What next for health care opportunities post Covid-19 vaccine?

Capital Group
clock • 1 min read
Partner Content: What next for health care opportunities post Covid-19 vaccine?

The Covid-19 vaccine was developed in under a year, an historic achievement for the global pharmaceutical industry. Could the health care sector produce more ‘miracles’ on this scale and see the sector excel?

In an age marked by global competition and rivalry, the Covid-19 vaccine effort was remarkable for the level of collaboration it engendered around the world. The effort featured the cooperation of a range of companies, governments, and academia, with billions of dollars of upfront government funding allowing companies to implement many steps in parallel that they would normally do in sequence. At a broader level, the lightning speed with which Covid-19 vaccines were developed has shown what the health care sector can achieve.  

Capital Group equity portfolio manager Rich Wolf, believes that advances in areas such as genetic analysis are paving the way for major breakthroughs in the treatment of various types of cancer, as well as massive potential profits for the companies that develop the drugs.  

"Therapies derived from genetic testing have the potential to extend lives and generate billions of dollars in revenue for the companies that successfully develop them," he said. 

Investment implications foreseen by Wolf and his colleague and equity investment analyst Laura Nelson Carney include a growing role for China - both as an end-user market and as a source of globally relevant innovation.  

And according to Wolf, if the 2010s were the era for technology titans (including the FAANGs) to lead markets and change the world, then the 2020s may well be the era when health care takes the lead.  

Click here to read the article in full and learn more about the growing number of life changing innovations on offer to investors in 2021 on the Future Forward hub. Brought to you by Investment Week, Professional Adviser and Capital Group.

More on Investment

Party politics: Why investors should celebrate AIM's 30th birthday, even if the government won't

Party politics: Why investors should celebrate AIM's 30th birthday, even if the government won't

AIM has helped 4,000 businesses raise £135bn since launch

Eustace Santa Barbara
clock 19 June 2025 • 4 min read
AIM at 30: Why advisers should take a fresh look at the UK's junior market

AIM at 30: Why advisers should take a fresh look at the UK's junior market

'We see AIM as a jewel in the crown with long-term appeal for the right clients'

Oliver Brown
clock 17 June 2025 • 4 min read
Taking the rough with the smooth: How to navigate global market volatility

Taking the rough with the smooth: How to navigate global market volatility

'Like investing, smoothing isn't one-size-fits-all'

James Tothill
clock 13 June 2025 • 4 min read

In-depth

Why Gen Z still trusts financial advisers in the age of finfluencers

Why Gen Z still trusts financial advisers in the age of finfluencers

A digital generation with a human touch

Sahar Nazir
clock 23 June 2025 • 4 min read
QROPS class actions: What next for frustrated UK expats?

QROPS class actions: What next for frustrated UK expats?

Calls for reform across the board as insurers fight back in IoM

Isabel Baxter
clock 29 May 2025 • 7 min read
AI on trial: FCA's Live Testing opens new path for advisers

AI on trial: FCA's Live Testing opens new path for advisers

Offering regulated firms a controlled space to trial advanced technologies

Sahar Nazir
clock 21 May 2025 • 7 min read